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all populations. We discussed this 
point in our paper, noting that our 
findings were from a very poorly 
malnourished population, similar to 
many populations in South Asia. The 
current WHO guidelines on the use of 
micronutrient powders recommend 
the use of micronutrient powders 
for children aged 6–23 months in 
populations in which the prevalence 
of anaemia is 20% or higher. In 
many low-income populations at 
risk for anaemia and micronutrient 
deficiencies, the observed rates of 
stunting and wasting would be 
similar to those that we encountered. 
As far as we are aware, there are no 
excluded subgroups or differential 
implementation in programmes, 
and future studies of micronutrient 
powders might explore this possibility.
Third, as discussed in our paper,1 we 
are uncertain about mechanisms for 
the observed respiratory eﬀ ects, but 
these ﬁ ndings are by no means unique. 
In the CIGNIS trial,3 increased rates of 
lower respiratory tract infections or 
pneumonia were reported in children 
receiving micronutrient fortified 
weaning food.  By contrast, the 
observations on diarrhoea in our study 
should not come as a great surprise. 
We disagree with Suchdev and Neufeld 
that the reported diarrhoea cases 
were all mild and that mechanisms 
are unclear. There was an increase in 
bloody diarrhoea and some evidence 
of an effect on severe diarrhoea 
(6+ stools although not achieving 
p<0·05). A recently published trial4 of 
micronutrient powders in a malaria 
endemic area of Africa reported an 
excess in hospital admissions due 
to all causes among children taking 
micronutrient powders containing iron 
during the 5-month supplementation 
period, with marginally higher rates 
of diarrhoea diagnosed in outpatient 
settings.  The statement that there is no 
clear pathophysiological mechanism 
for diarrhoea and no increase in speciﬁ c 
stool pathogens is incorrect. Among 
children receiving micronutrient 
powders we observed an excess of 
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essential—particularly for children with 
a high prevalence of undernutrition 
and disease burden, who tend to 
be more physically vulnerable—and 
robust evidence on the age-specific 
dose of daily multiple micronutrients 
supplementation is urgently needed.
There was almost no difference 
between the intervention and control 
groups in the tendency for the stunting 
rate to increase from baseline to 
24 months. The prevalence of stunting 
in the overall study population was 
high, even though basic counselling 
on breastfeeding and complementary 
feeding was provided. For such a 
population, a single intervention 
like multiple micronutrients tends 
to have limited eﬀ ects,2 and multiple 
micronutrients combined with 
protein energy are more eﬀ ective than 
multiple micronutrients alone.3 Rather, 
multifaceted interventions beginning 
in the prenatal and early postnatal 
periods need to be examined.4 
Improvement of the health and 
nutritional status of children begins 
with ensuring maternal nutritional 
health in pregnancy, the lactation 
period, and even pre-pregnancy. 
As young children’s nutritional 
status results from a complex 
interaction of various factors such 
as food consumption, safety of food 
and water, sanitation, nutritional 
knowledge of caretakers, and access to 
health care, an integrated strategy is 
necessary for their growth.5
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We thank Parminder Suchdev and 
Lynnette Neufeld for their comments 
on our study1 and the reservations 
expressed on the conclusions. 
First, the quality of evidence is 
questioned on three points: the trial 
was not placebo-controlled, the 
data for morbidity were captured by 
maternal recall, and the compliance 
rates of about 50% represent poor 
behaviour change. The vast majority 
of micronutrient powder trials to 
date have not used a placebo because 
there are challenges in manufacturing 
a safe placebo formulation for daily 
use. We acknowledge this limitation, 
common to most trials of micronutrient 
powders. We acknowledge (and 
discuss in our paper)1 the limitations of 
morbidity data derived from maternal 
recall. Many longitudinal studies use 
maternal reporting of morbidities and 
in our study1 this was accompanied by 
corroboration of reported maternal 
respiratory morbidities and assessment 
by trained community health workers. 
Our trial was designed to mimic as 
closely as possible what is feasible in 
real-life programmes, and we do not 
believe that the overall compliance 
represents poor behaviour change. 
The compliance observed over a 
12-month period is better than 
that reported in other effectiveness 
trials of micronutrient powders 
including the programmatic rollout 
in Kenya led by Suchdev,2 which only 
achieved an average consumption of 
0·9 micronutrient powder sachet per 
week. We believe the observed coverage 
is consonant with what is realistic in real 
life settings and if anything, makes our 
ﬁ ndings all the more important. 
Second, we did not claim that 
our findings are generalisable to 
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is key in preventing cardiovascular 
complications associated with 
hypertension.4 In our opinion,3 the 
Jikei Heart Study2 had no value if 
marketers would spread the message 
that valsartan, or for that matter any 
other antihypertensive drug, might 
confer beneﬁ ts beyond blood-pressure 
lowering. In conclusion, we should 
have been given full credit for our 
interpretation of the Jikei results, and 
we should not have been quoted in a 
way that might be misinterpreted.
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Aeromonas, a known pathogen causing 
diarrhoea.5 A number of studies have 
reported and discussed potential 
mechanisms for excess diarrhoea with 
use of iron. Future studies should be 
designed to explore this in greater 
depth.
Moreover, despite  the extra intake 
in both micronutrient powder groups 
and the existing programme for 
vitamin A supplementation, we did 
not observe any change in biochemical 
measures.
Fourth, we believe that the argument 
that the beneﬁ ts for growth are small 
but significant while the apparent 
effects on morbidity are small and 
therefore not signiﬁ cant is inconsistent. 
We want to re-emphasise that what we 
are calling for is a proper discussion of 
the benefits and potential harms in 
existing and future programmes of 
micronutrient powders. We hope that 
our ﬁ ndings from the largest trial of 
micronutrient powders in populations 
representative of urban and rural 
Pakistan, will spur further robust 
evaluation of the benefits and risks 
associated with this intervention.
We also thank Ruoyan Tobe-Gai 
and Rintaro Mori for their comment. 
Their point that the same iron dose 
should not be applied throughout 
the age range 6–18 months needs 
further evaluation and consideration 
by WHO. Changes in intestinal 
maturation throughout infancy could 
be important. These might require 
varying entry criteria for intervention 
and consideration of iron stores before 
trials of diﬀ erent doses. We also agree 
that micronutrient powders alone are 
not the solution in poorly nourished 
populations—a point that we noted 
in recommending alternative and 
additional strategies in our concluding 
statements. 
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Retraction of the Jikei 
Heart Study: 
misquotation of 
a Comment
The Lancet Editors recently announced 
(Sept 7, p 843)1 the retraction of the 
Jikei Heart Study. The Editors stated 
that when the Jikei Heart Study2 was 
ﬁ rst published, “Staessen and Richart3 
congratulated the investigators on 
their report.” However, this citation 
would have been much more 
balanced had the Editors also quoted 
the next sentence of our Comment:3 
“Nevertheless, one should not accept at 
face value the main conclusions of the 
Jikei report”. We clearly listed the many 
weaknesses of the study, including 
inadequate sample size, insufficient 
dosing of study medications, the 
weakness of soft endpoints, the open-
blinded-label endpoint assessment that 
did not account for bias in reporting 
endpoints by unblinded investigators, 
the between-group differences in 
blood pressure during the early phase 
of the randomised follow-up, and 
the lack of generalisability to general 
practice.  We were the ﬁ rst to show that 
blood pressure level, not drug class, 
Performance indicators 
and clinical excellence 
Attending post-intake ward rounds in 
various National Health Service (NHS) 
trusts around the UK, I am concerned 
that clinical expertise is being crowded 
out by a need to meet various key 
performance indicators. 
In one hospital, I was told on arrival 
that the trust had, over a year, moved 
from the bottom to the top category 
of performing trusts. I was therefore 
puzzled when soon thereafter 
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